Buy Cilostazol Online in Ireland

Overview of Cilostazol and its drug class

Cilostazol is a selective phosphodiesterase-3 (PDE3) inhibitor with antiplatelet and vasodilatory actions. By inhibiting PDE3, cilostazol elevates intracellular cAMP in platelets and vascular smooth muscle, thereby reducing platelet aggregation and promoting vasodilation; its principal clinical use is to improve walking distance in patients with intermittent claudication due to peripheral arterial disease.

The agent is administered orally and is subject to hepatic metabolism with active metabolites. Excretion occurs via renal and biliary routes. Therapeutic effect is achieved with ongoing therapy, and the drug is typically used as part of a broader program including supervised exercise and risk-factor modification. It is not indicated for acute coronary syndromes and has a distinct safety profile that requires consideration of bleeding tendency and cardiovascular effects.

How it compares to related substances in the same class

Within the PDE3 inhibitor class, cilostazol differs from intravenous agents such as milrinone and inamrinone, which are used acutely to support cardiac output in heart failure and carry inotropic effects. Cilostazol is an oral, long‑term therapy with combined antiplatelet and vasodilatory activity, rather than a primary inotrope.

Dipyridamole is another PDE inhibitor with vasodilator and antiplatelet properties, but it has a distinct pharmacokinetic profile and clinical niche. Compared with milrinone, cilostazol has a slower onset of action and a safety profile oriented toward chronic vascular symptoms rather than acute heart failure management.

Therapeutic uses

The principal indication is relief of intermittent claudication in peripheral arterial disease, with improved pain-free walking distance and maximal walking distance in appropriately selected patients. Therapy is typically combined with structured exercise and modification of cardiovascular risk factors. Cilostazol is not indicated for acute limb ischemia or as first-line therapy for other vascular conditions.

In stable patients, cilostazol may improve functional status during sustained therapy. Caution is advised for individuals with bleeding risks or concurrent antiplatelet therapy, as additive antiplatelet effects can increase bleeding potential. Routine monitoring includes assessment of bleeding, blood pressure, and heart rate given the vasodilatory component.

Key differences from similar medications

Table compares mechanisms, uses, and cautions for cilostazol and two related alternatives.

Safety profile summary

Cilostazol is generally well tolerated, with common adverse effects including headache, dizziness, palpitations, diarrhea, and abdominal discomfort. These effects are usually mild to moderate and tend to improve with continued use or dose adjustment.

Bleeding risk increases with concurrent antiplatelet therapy or anticoagulation due to additive effects on hemostasis. The drug is metabolized by hepatic cytochrome P450 enzymes, notably CYP3A4 and CYP2C19; strong inhibitors or inducers of these enzymes can alter cilostazol levels. Caution is advised in hepatic impairment, and therapy should be used with caution in patients with significant cardiovascular disease, particularly heart failure, and in the elderly. Use in pregnancy and lactation is not established and requires careful risk assessment.